StockNews.com assumed coverage on shares of Atrion (NASDAQ:ATRI – Free Report) in a research note published on Sunday morning. The brokerage issued a sell rating on the medical instruments supplier’s stock.
Atrion Stock Performance
Shares of ATRI opened at $459.92 on Friday. Atrion has a fifty-two week low of $274.98 and a fifty-two week high of $503.24. The company has a market capitalization of $809.46 million, a price-to-earnings ratio of 43.23 and a beta of 0.69. The firm has a 50-day simple moving average of $455.98 and a 200-day simple moving average of $429.96.
Atrion (NASDAQ:ATRI – Get Free Report) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.23 earnings per share for the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%. The business had revenue of $48.77 million during the quarter.
Institutional Investors Weigh In On Atrion
About Atrion
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.
Read More
- Five stocks we like better than Atrion
- The Significance of Brokerage Rankings in Stock Selection
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.